Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-19
2005-04-19
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S284100
Reexamination Certificate
active
06881743
ABSTRACT:
Selective MMP-13 inhibitors are pyridine derivatives of the formulaor a pharmaceutically acceptable salt thereof,wherein:R1and R2independently are hydrogen, halo, hydroxy, C1-C6alkyl, C1-C6alkoxy, C2-C6alkenyl, C2-C6alkynyl, NO2, NR4R5, CN, or CF3,E is independently O or S;A and B independently are OR4or NR4R5;R4and R5independently are H, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, (CH2)naryl, (CH2)ncycloalkyl, (CH2)nheteroaryl, or R4and R5when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted,n is an integer of from 0 to 6.
REFERENCES:
patent: 5130317 (1992-07-01), Baader et al.
patent: 5219847 (1993-06-01), Taguchi et al.
patent: 5260323 (1993-11-01), Baader et al.
patent: 5519038 (1996-05-01), Baader et al.
patent: 5852038 (1998-12-01), Ito et al.
patent: 5948780 (1999-09-01), Peterson, Jr. et al.
patent: 6008243 (1999-12-01), Bender et al.
patent: 6043263 (2000-03-01), Bar et al.
patent: 6307049 (2001-10-01), McIver et al.
patent: 20020151555 (2002-10-01), Barvian et al.
patent: 20020156061 (2002-10-01), Barvian et al.
patent: 20030078276 (2003-04-01), Adrianjara et al.
patent: 20030087924 (2003-05-01), Sorenson
patent: 20030229103 (2003-12-01), Weithmann et al.
patent: 2082076 (1993-05-01), None
patent: 1149356 (1963-05-01), None
patent: 0 409 119 (1991-01-01), None
patent: 0418797 (1991-03-01), None
patent: 0463592 (1992-01-01), None
patent: 0 541 042 (1993-05-01), None
patent: 0935963 (1999-08-01), None
patent: 1138680 (2001-10-01), None
patent: 9220676 (1992-11-01), None
patent: 0009485 (2000-02-01), None
patent: WO2000058288 (2000-10-01), None
patent: 0112611 (2001-02-01), None
patent: WO 0163244 (2001-08-01), None
patent: 0234726 (2002-05-01), None
patent: 0234753 (2002-05-01), None
patent: 02064571 (2002-08-01), None
patent: WO02064571 (2002-08-01), None
patent: WO02064080 A2 (2002-08-01), None
patent: WO02064547 A2 (2002-08-01), None
patent: 03049738 (2003-06-01), None
Hirota, et al., “Novel Synthesis of Pyrido[3,4-d]pyrimidines, Pyrido[2,3-d]-pyrimidines, and Quinazolines via Palladium-Catalyzed Oxidative coupling”, Heterocycles, 1994; 37(1):563-570.
Ye, et al., “Catalytic Domains of Matrix Metalloproteinases: A Molecular Biology Approach to Drug Discovery”, Curr.Med.Chem., 1996; 3:407-418.
Lovejoy, et al., “Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors”, Nature Structural Biol., 1999; 6:217-221.
Moy, et al., High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor, J. Mol. Biol., 2000; 302:671-689.
Mitchell, et al., “Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage”, J. Clin. Invest., 1996; 97(3):761-768.
Neuhold, et al., “Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice”, J. Clin. Invest., 2001; 107: 35-44.
Dahlberg. et al.. Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritic Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase I (Matrix Metalloproteinase 1), Arthrit. & Rheum., 2000; 43(3): 673-682.
Billinghurst, et al., “Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleuken-1 and the Selective Inhibition of Type II Collagen Cleavage by Collagenase”, Arthrit. & Rheum., 2000; 43(3): 664-672.
Billinghurst, et al., “Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage”, J. Clin. Invest., 1997; 99:1534-1545.
Milton J. et al., “Biaryl Acids: Novel Non-Nucleoside Inhibitors of HIV Reverse Transcriptase Types 1 and 2”, Bioorganic & Medicinal Chemistry Letters 1998, 8(19):2623-2628.
Chemical Abstracts CA Online! CASREACT AN 105:226286 of Vinsova, J. et al., “Antituberculotics XXXVII. Preparation of the functional derivatives of 6-methyl-2-pyridinecarboxylic acid substituted in position 4 and its 1-oxides” Cesk. Farm. 1985;34(10):430-436 (XP-002202692).
Hanauske-Abel, HM. et al., “Pyrroloquinoline quinone and molecules mimicking its functional domains. Modulators of connective tissue formation?” Federation of European Biochemical Studies Letters 1987, 214(2):236-243 (XP-002202687).
Rateb, L. et al., “Synthesis of heterocyclic compds. from delta-unsaturated 1,3-diketo-esters Part III. ethyl 3-cyano-6-styryl-2-pyridone-4-carboxylates and their degradation products” Journal of the Chemical Society 1960, 1430-1434 (XP-002202688).
Chemical Abstracts: AN 61:6987c “Preparation of pyridinedicarboxaldehydes” (XP-002202689), 1964.
Chemical Abstracts: AN 64:6607g “Compounds with potential antitubercular activity” (XP-002202690), 1966.
Chemical Abstracts: AN 55:10440b “Solubilizing agents. V. Pyridinecarboxamides” (XP-002202691), 1961.
Montana, John, et al, “The design of selective non-substrate-based matrix metalloproteinase inhibitors”, Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361.
Clark, Ian, et al, “Matrix metalloproteinase inhibitors in the treatment of arthritis”, Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25.
Chen, James, et al, “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design”, J. Am. Chem. Soc., 2000, 122; pp 9648-9654.
Barvian Nicole Chantel
Connor David Thomas
O'Brien Patrick Michael
Ortwine Daniel Fred
Patt William Chester
Ashbrook Charles W.
Morris Patricia L.
Pfizer Inc.
Purchase, Jr. Claude F.
Warner-Lambert & Company
LandOfFree
Pyridine matrix metalloproteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridine matrix metalloproteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridine matrix metalloproteinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3399363